Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 i-FACTOR + Matrix Launches in Canada - Orthopedic Design & Technology

What are you searching for?

Sign in
OEM News

i-FACTOR + Matrix Launches in Canada

Becomes the first market to offer the i-FACTOR+ MATRIX.

By: Cerapedics Inc.

Cerapedics’ i-FACTOR + MATRIX for surgical implantation has become fully commercially available in Canada.

“We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada  through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, CEO of Cerapedics, “Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.”

i-FACTOR + MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. Cerapedics initial P-15 technology product, i-FACTOR Peptide Enhanced Bone Graft, was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids or defects in orthopedic applications throughout the skeletal system (i.e., the spine and extremities). In the United States, i-FACTOR Peptide Enhanced Bone Graft was approved via a U.S. Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures.
 
“In addition to the commercial launch in Canada, the latest i-FACTOR+ MATRIX generation is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced. i-FACTOR+ Matrix is the same technology as the P15-L investigational material in the IDE,” said Jeffrey Marx, Ph.D., president and chief operating officer of Cerapedics.

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Add Orthopedic Design & Technology as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters

Topics